{
  "abstract": "We read with great interest the recent article by Tseng et al evaluating hepatitis B surface antigen (HBsAg) levels as a marker for surveillance of hepatocellular carcinoma (HCC) in patients with inactive chronic hepatitis B (CHB).1 Leveraging large, long-term cohorts from multiple sources and propensity score matching, the study adds important evidence to the ongoing debate over whether certain subgroups of hepatitis B e-antigen (HBeAg)-negative patients with normal alanine transaminase (ALT) and low hepatitis B virus (HBV) DNA truly require continued HCC surveillance. The authors’ demonstration that patients with HBsAg <100 IU/mL have a negligible risk of HCC is clinically meaningful. However, we wish to highlight several implications and pose questions to guide future research and practice.",
  "authors": [
    {
      "affiliations": [
        "JC School of Public Health and Primary Care, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong"
      ],
      "name": "Jing Chen"
    },
    {
      "affiliations": [
        "Liver Research Center, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China"
      ],
      "name": "Hong You"
    },
    {
      "affiliations": [
        "Humanity & Health Medical Centre, Hong Kong",
        "Zhongshan Hospital, Fudan University, Shanghai, China"
      ],
      "name": "George Lau"
    }
  ],
  "title": "Rethinking ‘Inactive Chronic Hepatitis B’: should we treat patients with high HBsAg levels?",
  "uid": "2c603dc6-200f-5cff-ba12-4ab1c76096c6"
}